Cited by 197Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Treatment

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., Ehler, E.·2014·European Journal of Pain

DOI 10.1002/j.1532-2149.2013.00445.x

Open this paper in CoChat — free account

Abstract

Background: Peripheral neuropathic pain (PNP) associated with allodynia poses a significant clinical challenge. The efficacy of Δ 9‐tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15‐week randomized, double‐blind, placebo‐controlled parallel group study. Methods: In total, 303 patients with PNP associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy. The co‐primary efficacy endpoints were the 30% responder rate in PNP 0–10 numerical rating scale (NRS) score and the mean change from baseline to the end of treatment in this score. Various key secondary measures of pain and functioning were also investigated. Results: At the 30% responder level, there were statistically significant treatment differences in favour of THC/CBD spray in the full analysis (intention‐to‐treat) dataset [p = 0.034; 95% confidence interval (CI): 1.05–3.70]. There was also a reduction in mean PNP 0–10 NRS scores in both treatment groups that was numerically higher in the THC/CBD spray group, but which failed to reach statistical significance. Secondary measures of sleep quality 0–10 NRS score (p = 0.0072) and S ubject G lobal I mpression of C hange (SGIC) (p = 0.023) also demonstrated statistically significant treatment differences in favour of THC/CBD spray treatment. Conclusions: These findings demonstrate that, in a meaningful proportion of otherwise treatment‐resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.

Integrity signals

Registry

Crossref · 10.1002/j.1532-2149.2013.00445.x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,178
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Prevalence of chronic pain with neuropathic characteristics in the general population
Bouhassira, D., Lantéri‐Minet, M., Attal, N., Laurent, B., & Touboul, C. (2007) · Pain · doi:10.1016/j.pain.2007.08.013 · Cited by 1,827
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Gabapentin for the Treatment of Postherpetic Neuralgia A Randomized Controlled Trial
Rowbotham, M. C. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,418
The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey
Torrance, N., Smith, B. H., Bennett, M., & Lee, A. J. (2006) · Journal of Pain · doi:10.1016/j.jpain.2005.11.008 · Cited by 1,001
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M. L., Hansson, P. T., Jensen, T. S., Nurmikko, T. J., Sampaio, C., Sindrup, S. H., & Wiffen, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 877
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study
Rice, A. S. C., & Maton, S. (2001) · Pain · doi:10.1016/s0304-3959(01)00407-9 · Cited by 596
Oral Opioid Therapy for Chronic Peripheral and Central Neuropathic Pain
Rowbotham, M. C., Twilling, L., Davies, P. S., Reisner, L. A., Taylor, K., & Mohr, D. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021420 · Cited by 529
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Self-citation
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., & Collet, J.-P. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.091414 · Cited by 450
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
Serpell, M. G. (2002) · Pain · doi:10.1016/s0304-3959(02)00255-5 · Cited by 431
Self-citation
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 8×
“…placebo (i.e., ‘psychiatric disorders’, ‘nervous system disorders’, ‘gastrointestinal disorders’ and ‘general disorders and administration site conditions’) have also been previously reported in other clinical trials with THC/CBD spray (Rog et al., 2005; Nurmikko et al., 2007; Wade et al., 2010).”
BackgroundResultInfluentialSelf-citation
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
The clinical picture of neuropathic pain
Jensen, T. S., Gottrup, H., Sindrup, S. H., & Bach, F. W. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01302-4 · Cited by 355
Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain: A Randomized Controlled Trial
Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327 · cited 2×
“…positive results in terms of pain scores (Serpell, 2002; Rowbotham et al., 2003), including studies in which vaporized cannabis (Wilsey et al., 2013) and cannabis cigarettes (Wilsey et al., 2008) were used, although slightly different pain scales were adopted than those used in the current study.”
Dissecting out mechanisms responsible for peripheral neuropathic pain: Implications for diagnosis and therapy
Woolf, C. J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.003 · Cited by 326
Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2012.10.009 · Cited by 314
Mechanism-based Pain Diagnosis
Woolf, C. J., & Max, M. B. (2001) · Anesthesiology · doi:10.1097/00000542-200107000-00034 · Cited by 306
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283
Self-citation
Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach
Baron, R., Förster, M., & Binder, A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70189-8 · Cited by 267
Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial
Boureau, F., Legallicier, P., & Kabir-Ahmadi, M. (2003) · Pain · doi:10.1016/s0304-3959(03)00020-4 · Cited by 231
Pregabalin for painful HIV neuropathy
Simpson, D. M., Schifitto, G., Clifford, D. B., Murphy, T. K., Cruz, E. D.-D., Glue, P., Whalen, E., Emir, B., Scott, G., & Freeman, R. L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ccc6ef · Cited by 197
Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187 · cited 3×
“© 2014 European Pain Federation - EFIC® Eur J Pain 18 (2014) 999–1012 1009 ports the consistent improvements in sleep seen in other clinical studies of this drug (Rog et al., 2005, 2007; Attal et al., 2006; Nurmikko et al., 2007).”
Background
An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174
Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy
Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., Petersen, K. L., Rowbotham, M. C., & Campbell, J. N. (2012) · Pain · doi:10.1016/j.pain.2012.04.014 · Cited by 165
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
Wade, D. T., Collin, C., Stott, C. G., & Duncombe, P. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367462 · Cited by 151
Basal Heat Pain Thresholds Predict Opioid Analgesia in Patients with Postherpetic Neuralgia
Edwards, R. R., Haythornthwaite, J. A., Tella, P. K., Max, M. B., & Raja, S. N. (2006) · Anesthesiology · doi:10.1097/00000542-200606000-00020 · Cited by 140
Designing Pain Research From the Patient's Perspective: What Trial End Points Are Important to Patients With Chronic Pain?
Casarett, D., Karlawish, J. H., Sankar, P. L., Hirschman, K. B., & Asch, D. A. (2001) · Pain Medicine · doi:10.1046/j.1526-4637.2001.01041.x · Cited by 111
Pharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases
Bačkonja, M.-M., & Serra, J. (2004) · Pain Medicine · doi:10.1111/j.1526-4637.2004.04020.x · Cited by 110
Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain
McQuay, H. J., Derry, S., Moore, A. R., Poulain, P., & Legout, V. (2008) · Pain · doi:10.1016/j.pain.2008.01.014 · Cited by 106
What should be the core outcomes in chronic pain clinical trials?
Turk, D. C., & Dworkin, R. H. (2004) · Arthritis Research · doi:10.1186/ar1196 · Cited by 98
Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion
Rasmussen, P. V., Sindrup, S. H., Jensen, T. S., & Bach, F. W. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00843.x · Cited by 43
Some philosophical considerations on pain
Degenaar, J. J. (1979) · Pain · doi:10.1016/0304-3959(79)90085-x · Cited by 29
Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?
Wade, D. T. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.12 · Cited by 20

Sorted by citations

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications
Haack, M., Simpson, N. S., Sethna, N. F., Kaur, S., & Mullington, J. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0439-z · Cited by 696
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F. W., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 606
Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460

See all 197

Authors: Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E.
Affiliations: Gartnavel General Hospital (GB)
MAC Clinical Research (United Kingdom) (GB)
General University Hospital in Prague (CZ)
West Suffolk Hospital (GB)
GW Pharmaceuticals (United Kingdom) (GB)
Nemocnice Pardubického Kraje (CZ)
Corresponding author: Serpell, M.
ORCID: Serpell, M.
Ehler, E.
Venue: European Journal of Pain
Publisher: Wiley
Published: 2014-01-13
Volume: 18
Issue: 7
Pages: 999-1012
ISSN: 1090-3801 (ISSN-L)
1532-2149
DOI: 10.1002/j.1532-2149.2013.00445.x
OpenAlex: W2112026566
Cited by: 197
References: 41
Citations by year: 2026: 8 · 2025: 14 · 2024: 15 · 2023: 12 · 2022: 32 · 2021: 24 · 2020: 25 · 2019: 15 · 2018: 20 · 2017: 10 · 2016: 10 · 2015: 9 · 2014: 3
FWCI: 7.78
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: European Journal of Pain (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords: peripheral neuropathic pain, allodynia, oromucosal spray, cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, sleep quality, treatment-resistant pain, tolerability
MeSH terms: Adult, Aged, Aged, 80 and over, Analgesics, Cannabidiol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Peripheral Nervous System Diseases, Dronabinol, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks